remacemide has been researched along with Cerebrovascular Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borrelli, AR; Cregan, EF; Palmer, GC; Willett, F | 1 |
| Dyker, AG; Lees, KR | 1 |
1 review(s) available for remacemide and Cerebrovascular Disorders
| Article | Year |
|---|---|
Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride.
Topics: Acetamides; Animals; Anticonvulsants; Brain; Cats; Cell Survival; Cerebrovascular Disorders; Disease Models, Animal; Humans; Hypoxia, Brain; Ischemic Attack, Transient; Mice; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Inbred SHR; Receptors, N-Methyl-D-Aspartate; S100 Calcium Binding Protein G; Subarachnoid Hemorrhage | 1995 |
1 trial(s) available for remacemide and Cerebrovascular Disorders
| Article | Year |
|---|---|
Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Topics: Acetamides; Acute Disease; Adult; Aged; Aged, 80 and over; Brain Ischemia; Central Nervous System Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Neuroprotective Agents; Placebos | 1999 |